tirzepatide death In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx GROUNDBREAKING UPDATE! FDA has approved

GLP-1 triggers the release of insulin which in turn allows your body to utilize the glucose derived from food as a source of energy

Liver Disease (MASH/NASH) The growing burden of metabolic liver disease is creating a massive new opportunity

Counsel patients regarding the potential risk for MTC with the use of (MOUNJARO OR ZEPBOUND) and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness)

Patients and healthcare professionals should exercise caution regarding unregulated sources

Plant-based eaters can become deficient over time, so supplementation (oral or injected) may be needed